This research paper evaluates the safety and efficacy of obicetrapib, a cholesteryl ester transfer protein inhibitor, in patients at high cardiovascular risk already receiving lipid-lowering therapy. The study, a randomized, placebo-controlled trial, found that obicetrapib significantly reduced low-density lipoprotein (LDL) cholesterol levels compared to placebo over 84 days. While the trial was not powered to assess cardiovascular events, it observed a numerical decrease in events in the obicetrapib group. The paper concludes that obicetrapib could be a valuable addition for managing high LDL cholesterol in this patient population, although longer-term studies and broader demographic representation are needed to fully understand its effects and generalizability. ***Episode is read by an automated AI-assisted voice.